Tag: newsroom

LEWES, Del., July 11, 2025 (GLOBE NEWSWIRE) -- Zeebu, the decentralised protocol powering programmable settlement infrastructure for institutional payments, has officially crossed $9 billion in total volume settled. This milestone reflects not just scale, but the operational maturity of Zeebu’s blockchain-native clearing system, one designed to replace reconciliation-heavy financial processes with instant, verifiable, and value-aligned transaction flows.

빅토리아, 세이셸, July 11, 2025 (GLOBE NEWSWIRE) -- 암호화폐 거래소이자 웹3.0 회사인 Bitget이 솔라나 기반 멤코인 플랫폼 펌프닷펀(pump.fun)의 네이티브 토큰인 펌프닷펀(PUMP)의 공개 토큰 세일 개시에 들어갔다.

SHREWSBURY, United Kingdom, July 10, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a next-generation Layer 1 blockchain built for AI-powered applications, today announced the launch of its Bonus Round, marking a significant milestone after successfully closing all 15 presale stages with $21.1 million in total contributions. As part of its next phase of ecosystem expansion, Lightchain AI has officially rolled out its staking infrastructure and launched a $150,000 developer grant program to support dApp development and community innovation.

SHREWSBURY, United Kingdom, July 10, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a performance-focused Layer 1 blockchain built for AI-native applications, today announced a strategic move in its tokenomics as it enters the Bonus Round of its presale campaign. Following the successful completion of all 15 presale stages and the raise of over $21 million, Lightchain AI has officially reallocated its original 5% team token allocation entirely toward ecosystem development initiatives.

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

BALI, Indonesia, July 10, 2025 (GLOBE NEWSWIRE) -- Global Recognition Awards™ has honored Viceroy Bali with a 2025 Global Recognition Award for Bali’s Best Luxury Resort, celebrating the property’s outstanding achievements in luxury hospitality and its ongoing commitment to excellence in the industry. The award recognizes the resort's exceptional standards in luxury hospitality, following its previous recognition as the World's #1 Resort by Condé Nast Traveler in 2018 and multiple World Luxury Hotel Awards, including Best Luxury Honeymoon Resort Worldwide in 2024.

In Partnership with the California New Car Dealers Association (CNCDA), DCG to Host Private Gathering for Industry Leaders During Monterey Car Week